Brokerages Set Vaxcyte, Inc. (NASDAQ:PCVX) PT at $136.50

Vaxcyte, Inc. (NASDAQ:PCVX) has been assigned an average recommendation of “Buy” from the ten analysts that are presently covering the stock, MarketBeat reports. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $136.50.

Several research firms recently commented on PCVX. Needham & Company LLC restated a “buy” rating and issued a $90.00 price target on shares of Vaxcyte in a report on Tuesday, April 8th. Evercore ISI raised Vaxcyte to a “strong-buy” rating in a research note on Monday, March 31st. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Cantor Fitzgerald initiated coverage on Vaxcyte in a report on Tuesday, April 22nd. They set an “overweight” rating for the company. Finally, Guggenheim restated a “buy” rating and issued a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th.

Vaxcyte Trading Up 0.6%

Shares of NASDAQ PCVX opened at $37.20 on Thursday. Vaxcyte has a 52 week low of $27.66 and a 52 week high of $121.06. The stock has a market cap of $4.80 billion, a price-to-earnings ratio of -8.09 and a beta of 1.20. The company’s 50-day moving average price is $32.33 and its 200 day moving average price is $64.42.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same period in the prior year, the business earned ($0.85) EPS. As a group, research analysts expect that Vaxcyte will post -4.21 earnings per share for the current year.

Institutional Trading of Vaxcyte

Large investors have recently bought and sold shares of the stock. Rhumbline Advisers grew its holdings in shares of Vaxcyte by 5.5% during the first quarter. Rhumbline Advisers now owns 181,230 shares of the company’s stock worth $6,843,000 after purchasing an additional 9,416 shares during the last quarter. Strs Ohio acquired a new stake in shares of Vaxcyte during the first quarter worth about $627,000. Intech Investment Management LLC grew its holdings in shares of Vaxcyte by 44.3% during the first quarter. Intech Investment Management LLC now owns 89,212 shares of the company’s stock worth $3,369,000 after buying an additional 27,384 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Vaxcyte by 8.7% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock worth $19,409,000 after buying an additional 41,034 shares in the last quarter. Finally, Caxton Associates LLP bought a new position in Vaxcyte in the first quarter valued at approximately $226,000. 96.78% of the stock is currently owned by institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.